EMR data to assess monitoring of patients treated with quetiapine
Study identifier:D1443C00128
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Objective assessment of metabolic monitoring in patients treated with Seroquel® or Seroquel® XR/quetiapine fumarate: use of IMS Disease Analyzer to assess physician behaviour in the UK and Germany
Medical condition
schizophrenia
Phase
N/A
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
800
Study type
Observational
Age
N/A
Date
Study Start Date: 01 Apr 2013
Primary Completion Date: 01 Jun 2013
Study Completion Date: 01 Jun 2013
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Oct 2015 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| GER All patients with a diagnosis of schizophrenia, bipolar disorder or major depressive disorder treated with Seroquel® or Seroquel® XR seen by general practitioners and psychiatrists in Germany based upon patient encounters recorded in IMS Disease Analyzer during the calendar period 13 February 2012 - 31 August 2012 | - |
| UK All patients with a diagnosis of schizophrenia, bipolar disorder or major depressive disorder treated with Seroquel® or Seroquel® XR seen by general practitioners in the United Kingdom based upon patient encounters recorded in IMS Disease Analyzer during the calendar period from 11 January 2012 - 31 July 2012 | - |
Contacts
Investigators
Principal Investigator
Robert S Brody
AZ
